NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Denali Therapeutics Inc. Common Stock (DNLI) Stock Analysis

Denali Therapeutics Inc. Common Stock (DNLI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DNLI

$22.28

−$0.52 (−2.28%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DNLI with… →

DNLI Key Statistics

As of Sep 4, 2026
Trading
Open
$22.32
Previous Close
$22.80
Day's Range
22.15–22.48
52-Week Range
12.58–27.30
Volume
799.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.00
Valuation
Market Cap
$3.56B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
988.18
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.78
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$512.54M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
159.85M
1-Year Return
+50.64%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.65M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DNLI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+34.95%
2025−18.99%
2024−5.03%
2023−22.83%
2022−37.65%
2021−46.75%
2020+380.83%
2019−15.68%
2018+32.10%
2017 (partial year)−27.09%

As of September 4, 2026.

DNLI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$512.54M—
2024$0.00−$422.77M—
2023$330.53M−$145.22M−43.9%
2022$108.46M−$325.99M−300.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$555.34M−$512.54M—
2024$0.00—−$501.88M−$422.77M—
2023$330.53M—−$196.70M−$145.22M−43.9%
2022$108.46M—−$340.74M−$325.99M−300.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DNLI Valuation vs Biotechnology Median

Median of 656 stocks
MetricDNLIBiotechnology medianvs median
P/S ratio988.1815.2664.7x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Denali Therapeutics Inc. Common Stock (DNLI) at $3.56B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 503.

The most recent close on file for DNLI is $22.28, dated September 4, 2026. That is −$0.52 (−2.28%) against the previous close. Over the past 52 weeks the price has ranged from $12.58 to $27.30. The latest close sits 77.11% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $512.54M. Profit margin runs at 0%. Trailing earnings per share are −2.78.

Across the 4 fiscal years on file, revenue moves from $108.46M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 988.18 times revenue. On price-to-sales that is 64.7 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 1.01. Annualized volatility over the trailing 8 years is 65.07%. The trailing one-year price return is +50.64%. Across 5 years the annualized return works out at −16.39%.

Growth & Income

No dividend is on file for DNLI.

The strongest complete calendar year on file is 2020 at +380.83%; the weakest is 2021 at −46.75%. Of the 8 complete calendar years on file, 2 finished higher. So far in 2026 the price is +34.95%.

Peer Comparison

Denali Therapeutics Inc. Common Stock (DNLI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Denali Therapeutics Inc. Common Stock DNLI $3.56B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Denali Therapeutics Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Denali Therapeutics Inc. Common Stock

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Visit website →